Sanuwave Health's third quarter showed the CMS reimbursement overhang landing on the business. The company lost $0.16 per share on revenue of $8.58 million. Earnings fell 134.8% year over year and revenue fell 25.1%. The company's release cites a 24% decline, a rounding and presentation difference rather than a substantive one. No consensus estimate was available, so this quarter cannot be read as a beat or a miss. The relevant question is trajectory, and the trajectory is decisively worse. Revenue has decelerated in every quarter of the year: +30% in Q4 FY25, +3% in Q1, -3% in Q2 and now -24% in Q3. Full-year guidance of $51-55 million, withdrawn in Q2, was not reinstated even though the final CMS rule has now been published.

The year-over-year earnings collapse overstates the operating deterioration, but only somewhat. Last year's $9.7 million net income was inflated by a $6.1 million non-cash derivative gain and a one-time $5.0 million patent sale gain. Strip those out and the cleaner comparison is operating income. That measure swung from a $0.9 million profit to a $1.1 million loss, which still represents real erosion. Adjusted EBITDA fell to $0.7 million from $3.2 million a year ago, and the sequential slide is just as telling: $4.8 million in Q4 FY25, $1.1 million in Q1, $1.2 million in Q2 and now $0.7 million. Cost control was not the problem. Operating expenses of $7.7 million were slightly below last year, and gross margin held at 77.3%, up from 76.2% in Q2. Interest expense also dropped to $0.3 million from $1.8 million after last year's refinancing. The damage was almost entirely on the top line.

That top-line story splits into two very different businesses. Capital equipment fell apart. Only 40 Ultramist systems were sold, versus 155 a year ago, 82 in Q2 and 255 in Q4 FY25. System revenue fell 73% to $1.2 million. Management blamed several forces:

• practitioners adopting a "wait and see" posture during the proposed-rule period;
• mobile and rural wound care operators exiting after CMS held 2027 skin-substitute pricing flat;
• a growing secondary market for used units that it expects to persist into Q4 and possibly 2027.

The recurring side held up better. Applicator units rose 15% and consumables, parts and accessories revenue grew 5% to $7.2 million. Even here the quality is softening. An 11% applicator price decline from reseller mix limited applicator revenue growth to 2%, down from 13% in Q2, and applicator revenue fell about 4% sequentially. The company also discontinued its active-systems metric, which had been rising each quarter, citing low data resolution. Investors lose a useful window into the installed base just as it matters most.

The reimbursement picture is genuinely two-sided, and that is the central tension for the stock. The CEO's release commentary focuses on the proposed rule's effect during the quarter. The call, however, addressed the final rule, which locked in a roughly 21% cut to the 97610 physician fee schedule rate, to about $314.54 from $397.81, with further reductions expected in 2028. Against that, the hospital outpatient rate rises about 14% to roughly $235. The code also moves from packaged status to separately payable, which matters because more than half of 2025 outpatient treatments were effectively paid at zero. The AMA RUC has asked CMS to delay, and CMS has invited data on scaling factors for wound size, depth and count. Management frames that as a path to a restructured code in the 2028 proposed rule, but that is a mid-2027 event at the earliest. Nearer term, 60 new customers and early traction in hospital pressure-injury programs offer some evidence that the hospital pivot is more than aspirational.

The balance sheet is where bears have the most legitimate ammunition:

• Cash fell to $6.6 million from $12.0 million at year-end, after $4.3 million of term-loan principal payments and sales-tax disclosure settlements, including about $2.3 million paid in the quarter.
• Roughly $17 million of term debt remains, $5.7 million of it current.
• Sanuwave breached its fixed charge coverage covenant at quarter-end and needed a JPMorgan waiver and amendment on October 28.
• Shareholders' equity stands at just $2.9 million.
• The risk factors reference regaining Nasdaq listing compliance.

The market had already priced in considerable damage before this report. Shares opened at $5.95 after the August release, less than half the 200-day moving average of $12.74. That gap signals a stock that has been in a sustained downtrend through the reimbursement saga.

The bottom line is that Q3 removed much of the uncertainty around reimbursement, mostly in the wrong direction for the company's core physician-office market. Recurring consumable volume and the outpatient rate changes keep a credible long-term thesis alive, but that thesis is now a 2027-2028 story. In the meantime, Sanuwave must manage collapsing system sales, used-unit cannibalization, thin cash and a covenant waiver.